
The need to move beyond a point-solutions approach to one built around applications designed to manage the end-to-end clinical trial process is crucial.
Jennifer Goldsmith is vice-president of Vault at Veeva Systems.
The need to move beyond a point-solutions approach to one built around applications designed to manage the end-to-end clinical trial process is crucial.
While launching a new clinical study is an exciting stage of product development for trial personnel, road blocks can emerge. A new approach is needed to cope with the volume of activates required for the study product registration.
Published: June 2nd 2016 | Updated:
Published: August 1st 2016 | Updated: